



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

30 March 2023
EMA/286179/2023
Human Medicines Division

Statement indicating compliance with the agreed completed paediatric investigation plan

Medicinal product

Entresto/ sacubitril / valsartan

Pharmaceutical form(s):	See Annex A of the CHMP Opinion
Strength(s):	See Annex A
Route(s) of administration:	See Annex A
Packaging and package size(s):	See Annex A
Number(s) in the Community Register of Medicinal Products:	See Annex A

Marketing Authorisation Holder (MAH):

Name and address of the MAH:	Novartis Europharm Limited Vista Building Elm Park Merrion Road Dublin 4 IRELAND
------------------------------	---

Procedure

Procedure number:	EMA/H/C/004062/X/0044/G
-------------------	-------------------------

Further to the compliance check performed under Article 23 of Regulation (EC) No 1901/2006, and in accordance with Article 28(3) and Article 45(3) of the said Regulation it is concluded that:

- the development of this product has complied with all measures in the agreed paediatric investigation plan P/0327/2021. All studies in the agreed paediatric investigation plan P/0327/2021 were conducted after the entry into force of that Regulation,
- the Summary of Product Characteristics reflects the results of studies conducted in compliance with this agreed paediatric investigation plan.

In accordance with Article 23a of Regulation (EC) No 1234/2008, this statement indicating compliance with the agreed completed paediatric investigation plan P/0327/2021 is included in the technical dossier.

